Ignacio Heras-Murillo

Ignacio Heras-Murillo

Auto-generated profile, based on publicly available information

Ignacio Heras-Murillo

Immunobiology lab Centro Nacional de Investigaciones Cardiovasculares (CNIC) Madrid 28029 Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
SWStefanie K. Wculek
Stefanie K. Wculek
GDGillian Dunphy
Gillian Dunphy
IHIgnacio Heras-Murillo
Ignacio Heras-Murillo
AMAnnalaura Mastrangelo
Annalaura Mastrangelo
David SanchoDavid Sancho
David Sancho
Cellular metabolism orchestrates the intricate use of tissue fuels for catabolism and anabolism to generate cellular energy and structural components. The emerging field of immunometabolism highlights the importance of cellular metabolism for the maintenance and activities of immune cells. Macrophages are embryo- or adult bone marrow-derived leukocytes that are key for healthy tissue homeostasis but can also contribute to pathologies such as metabolic syndrome, atherosclerosis, fibrosis or cancer. Macrophage metabolism has largely been studied in vitro. However, different organs contain diverse macrophage populations that specialize in distinct and often tissue-specific functions. This context specificity creates diverging metabolic challenges for tissue macrophage populations to fulfill their homeostatic roles in their particular microenvironment and conditions their response in pathological conditions. Here, we outline current knowledge on the metabolic requirements and adaptations of macrophages located in tissues during homeostasis and selected diseases.

20 October 2023 in Advanced Science
Verified
Journal Article
Open access
RLRodrigo Lázaro‐Gorines
Rodrigo Lázaro‐Gorines
PRPatricia Pérez Ramírez
Patricia Pérez Ramírez
IHIgnacio Heras‐Murillo
Ignacio Heras‐Murillo
IAIrene Adán‐Barrientos
Irene Adán‐Barrientos
GBGuillermo Albericio Bonilla
Guillermo Albericio Bonilla
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS‐CoV‐2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross‐priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT, are first generated by grafting an anti‐RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo‐EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high‐avidity neutralizing interaction. Then, by C‐terminal fusion of an anti‐DNGR‐1 scFv to TNT, the bispecific trimerbody TNTDNGR‐1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross‐priming. Therapeutic administration of TNTDNGR‐1, but not TNT, protects K18‐hACE2 mice from a lethal SARS‐CoV‐2 infection, boosting virus‐specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus‐neutralizing antibody activity and demonstrate the therapeutic potential of the Fc‐free strategy that can be used advantageously to provide both immediate and long‐term protection against SARS‐CoV‐2 and other viral infections.